Engineered CAR-T cells offer potential rheumatoid arthritis cure

Professor Min Peng, corresponding author and researcher at Tsinghua University's Institute for ImmunologyExisting anti-TNF biologics rely on neutralization rather than degradation, while all current targeted protein degradation tools borrow the host's endogenous protein degradation machinery-an approach that can introduce unpredictable side effects and fundamentally limits durability. By recruiting an exogenous cellular platform-CAR-T cells-to perform the degradation, we bypass this limitation entirely. Our vision is a one-time intervention that provides years of sustained benefit for patients with chronic inflammatory disease."

This work was conducted at the State Key Laboratory of Molecular Oncology, Institute for Immunology, and School of Basic Medical Sciences, Tsinghua University, Beijing, China, in collaboration with Shanxi Medical University. Support was provided by the National Natural Science Foundation of China (Grant Nos. T2495270 and 82350108), the Tsinghua University DUSHI Program (Grant No. 52302102323), the Tsinghua-Peking Center for Life Sciences, and the SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine.

Source:

SciOpen

Journal reference: